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Background: The concept of hybrid coronary revascularization (HCR) combines the left internal mammary artery
(LIMA)–left anterior descending (LAD) graft and percutaneous coronary intervention (PCI) to non-LAD vessels. Multiple
comparative studies have evaluated the safety and feasibility of HCR and coronary artery bypass grafting (CABG) for
multivessel coronary artery disease (MCAD). However, the sample size of each study was small, and evidences based on
single-institutional experience. The purpose of this meta-analysis was to compare the short-term outcomes of HCR with
those of CABG for MCAD.
Method: PubMed, EMBASE and Cochrane Library databases, as well as conference proceedings, were searched for
eligible studies published up to March 2014. We calculated summary odds ratios (OR) for primary endpoints (death,
stroke; myocardial infarction (MI); target vessel revascularization (TVR); major adverse cardiac or cerebrovascular events
(MACCEs)) and secondary endpoints (atrial fibrillation (AF); renal failure; length of stay in the intensive care unit (LoS in
ICU); length of stay in hospital (LoS in hospital); red blood cell (RBC) transfusion). Data from 6176 participants were
derived from ten cohort studies.
Results: HCR was non-inferior to CABG in terms of MACCEs during hospitalization (odds ratio (OR), 0.68, 95%
confidence interval (CI), 0.34–1.33)and at one-year follow-up(0.32, 0.05–1.89) , and no significant difference was
found between HCR and CABG groups in in-hospital and one-year follow-up outcomes of death, MI, stroke, the
prevalence of AF and renal failure, whereas HCR was associated with a lower requirement of RBC transfusion
and shorter LoS in ICU and LoS in hospital than CABG (weighted mean difference (WMD) –1.25, 95% CI, –1.62 to
–0.88; –17.47, –31.01 to –3.93; –1.77, –3.07 to –0.46; respectively).
Conclusion: Our meta-analysis indicates that HCR is feasible, safe and effective for the treatment of MCAD, with
similar in-hospital and one-year follow-up outcome, significantly lower requirement of RBC transfusion, and faster
recovery compared with CABG.
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Table 1 Newcastle-Ottawa scale used for methodological
quality assessment of non-RCT
Check list
Selection
1、 Assignment for treatment: any criteria reported?
(if yes, 1 star)
2、 How representative was the reference group (CABG)
in comparison with the general elderly population for
CABG? (if yes,1 star; 0 star if the patients were selected
or selection of group was not described)
3、 How representative was the treatment group (HCR) in
comparison with the elderly population for CABG?
(if drawn from the same community as the reference
group, 1 star; 0 star if drawn from a different source or
selection of group was not described)
Comparability
4、 Group comparable for 1, 2, 3, 4,5 (if yes, 2 stars; one
star was assigned if one of these five characteristics
was not reported even if there were no other
differences between the two groups and other
characteristics had been controlled for; 0 star was
assigned if the two groups differed)
5、 Group comparable for 6, 7, 8,9,10 (if yes, 2 stars; one
star was assigned if one of these four characteristics
was not reported even if there were no other
differences between the two groups and other
characteristics had been controlled for; 0 star was
assigned if the two groups differed)
Outcome
assessment
6、 Clearly defined outcome of interest (yes, 1 star
for information ascertained by record lincage or
interview; 0 star if this information was not reported)
7、 Adequacy of follow-up (1 star if follow-up above 90%)
Comparability variables: 1 = age; 2 = gender; 3 = diabetes; 4 = hypertension;
5 = hypercholesterolemia; 6 = history of cerebrovascular disease; 7 = previous
PCI; 8 = previous MI; 9 = smoking; 10 = PVD.
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The revascularization strategy for multivessel coronary
artery disease (MCAD) is associated with advantages
and disadvantages. Coronary artery bypass grafting
(CABG; on-pump and off-pump) offers superior long-
term advantages owing largely to the left internal mam-
mary artery (LIMA) to the left anterior descending
(LAD) artery graft [1,2]. Conversely, CABG is a relatively
aggressive surgical procedure with a higher risk of post-
operative stroke [1,3-5], and conduits via the saphenous
vein graft have comparatively short-term patency [6,7].
In contrast, percutaneous coronary intervention, a much
less invasive method, carries a minimal procedural risk
as well as a lower prevalence of failure for the target ves-
sel due to the use of drug-eluting stents (DES) [8,9].
However, those benefits come at the expense of the need
for repeat revascularization [2].
The concept of hybrid coronary revascularization
(HCR), which combines the LIMA–LAD graft and per-
cutaneous coronary intervention (PCI) to non-LAD
vessels, was first introduced by Angelini and colleagues
in 1996 [10]. Introduction of HCR has led to concerns
as to whether HCR is superior to CABG for MCAD.
Multiple comparative studies have evaluated the safety
and feasibility of HCR and CABG for MCAD. However,
the sample size of each study was small, and evidences
based on single-institutional experience [11-21]. The
purpose of this meta-analysis was to compare the




Study selection and search strategy
Two independent reviewers (P.Z, and P.Y.Z) searched
PubMed, Embase, Web of Science, and the Cochrane Li-
brary for randomized controlled trials (RCTs) and non-
RCTs up to 1 March 2014 and compared HCR with
CABG for MCAD without language or publication re-
strictions. The following medical subject heading terms
and their variants were used in database searches: hybrid
coronary revascularization; coronary artery bypass graft-
ing (on-pump or off-pump); multivessel coronary artery
disease. Reference lists within selected studies and ab-
stracts published at major international conferences
were also searched.
Outcome measures
The safety endpoints of this meta-analysis were death,
stroke, myocardial infarction (MI) and major adverse
cardiac or cerebrovascular events (MACCEs). The effi-
cacy endpoint was revascularization. All the primary
endpoints were measured in hospital and one year of
follow-up. Death was defined as death from any cause.MI was diagnosed by symptoms, electrocardiography
and changes in serum levels of cardiac biomarkers. Tar-
get vessel revascularization (TVR) was the need for re-
peated CABG or percutaneous coronary intervention
(PCI). MACCEs were defined as a composite of death,
MI, stroke or revascularization.
Secondary outcomes were atrial fibrillation (AF),
renal failure (defined as an increase in serum creatinine
values >25% above baseline values), length of stay in
the intensive care unit (LoS in ICU), length of stay in
hospital (LoS in hospital), and transfusion of red blood
cells (RBCs).Criteria for eligibility of inclusion of studies
Five main criteria were used: (i) comparison of HCR with
CABG for MCAD; (ii) studies reporting at least one of the
outcomes mentioned above; (iii) studies documenting sur-
gical procedures such as one-stop HCR or staged HCR,
Figure 1 Flowchart of study identification and selection following PRISMA statement.
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methods such as HCR or CABG; (iv) follow-up duration
≥30 days; (v) non-RCTs with a score >5 as assessed by the
Newcastle–Ottawa Scale (NOS) [22-24].Assessment of the methodological quality of included studies
Three independent authors (Y.S., M.M.J, and Y.L.G)
assessed the methodological quality of the included stud-
ies, and disagreement was resolved by consensus and
discussion. Quality of non-RCTs was evaluated with the
modified NOS (http://www.ohri.ca/programs/clinical_
epidemiology/oxford.asp), which addressed three items:
patient selection, comparability of groups, and outcome
assessment (Table 1).Statistical analyses
We undertook statistical analyses using Revman v5.2
(Cochrane Collaboration, Oxford, UK). Continuous and
dichotomous variables were assessed by weighted mean
differences (WMDs) and odds ratios (OR), respectively. A
95% confidence interval (CI) was recorded. Heterogeneity
among studies was quantified using the I2 statistic.
According to Higgins’ method, I2 < 25%, 25–50%, and >50
% were defined as low, moderate, and high heterogeneity,
respectively [25]. A fixed-effect model was applied when I2
< 50%, and a random-effect model employed if I2 was
>50%. P < 0.05 was considered significant. Sensitivity ana-
lyses were done on primary outcomes by changing the effects
model and adjusting inclusion criteria. Publication bias was
analyzed by funnel plots and evaluated by Egger’s test.
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We identified ten studies eligible for inclusion: nine
non-randomized and one randomized (Figure 1 and
Table 2), All of the non-RCTs had a NOS score >5
[11,12,14,16-21], which was considered to denote a high-
quality trial (Table 3). Figure 1 details the process of the
identification and selection of studies following the
PRISMA statement [26]. Baseline characteristics of pa-
tients in the Studies included is shown in Table 4. All
studies combined represent outcome data on 6176 pa-
tients who underwent HCR(n = 623) or CABG surgery
(n = 5553) from 2007 until present.
Early outcomes (in hospital)
Primary clinical outcomes
Death Five studies reported on in-hospital mortality in
5770 patients. Pooled results showed no significant dif-
ference in mortality between the HCR group and
CABG group <1 month (OR: 1.21; 95% CI: 0.55–2.62;
P = 0.64; Figure 2A).
MI Patients treated with HCR did not display a signifi-
cant reduction in risk for MI as compared with those
who received CABG within hospital (OR: 0.69; 95% CI:
0.21–2.24; P = 0.54; Figure 2B). Heterogeneity was not
observed in this analysis (I2 = 3%).
Stroke Stroke was assessed in five studies reporting on
5793 patients. The prevalence of stroke was not signifi-
cantly different between groups. (OR: 1.12; 95% CI:Table 2 Main characteristics of included studies
Study Year Numbers of patients
(HCR/CABG)
Stud
Kon [17] 2007 15/30 Non
Zhao [11] 2008 112/254 Non
Reicher [14] 2007 13/26 Non
Vassiliades [12] 2009 91/4175 Non
Delhaye [20] 2010 18/18 Non
Hu [18] 2010 104/104 Non
Halkos [19] 2011 147/588 Non
Bachinsky [21] 2012 25/27 Non
Leacche [16] 2012 80/301 Non
Popov [15] Unpublished 18/30 RCT
Unless otherwise indicated, data are expressed as mean ± standard deviation.
PCI, percutaneous coronary intervention; OPCABG, on-pump coronary artery bypass
NR: not reported.0.44–2.86; P = 0.81; Figure 2C). Heterogeneity was not
observed in this analysis (I2 = 0%).
TVR We analyzed the prevalence of TVR described in
the five articles. For four studies, no event occurred in
both groups, so we could not undertake a meta-analysis
on the prevalence of TVR. In summary, there was insuf-
ficient evidence to show that the prevalence of TVR was
different between HCR group and CABG group.
MACCEs MACCEs occurred in 2.5% (10/408) of pa-
tients after HCR and 3.6% (181/5092) of patients with
CABG.Six studies (5500 patients) provided data on the
prevalence of MACCEs. Pooling of the outcomes of
these studies revealed no significant differences in the
prevalence of MACCEs between patients treated by
HCR and those treated by CABG (OR: 0.68; 95% CI:
0.34–1.33; P = 0.26; Figure 2E). Slight heterogeneity was
detected in this analysis (I2 = 2%).
Secondary clinical outcomes
Five studies reported on AF. [11,16,18,19,21] Four studies
reported renal failure [11,16,17,19,20]. Six studies reported
LoS in ICU [14,15,17-19,21]. Five studies reported LoS in
hospital [14,17-19,21]. Three studies reported transfusion
of RBCs [14,17,21].
There was no significant difference in the prevalence
of AF between the two groups (OR: 0.93; 95% CI: 0.70–
1.23, P = 0.60) or the prevalence of renal failure (OR:
0.73; 95% CI: 0.36–1.49; P = 0.39).y design CABG HCR strategy Follow-up
(months)
-RCT OPCABG Simultaneous 12
-RCT On-pump Simultaneous NR
-RCT OPCABG Simultaneous 14




-RCT On-pump CABG then PCI 12
OPCABG then PCI
-RCT OPCABG Simultaneous 18 ± 7.9
-RCT OPCABG Mainly staged 38.4 (median)
-RCT OPCABG Simultaneous 1
-RCT OPCABG NR 1
On-pump MICABG then PCI 1
grafting; MICABG, minimally invasive coronary artery bypass grafting;
Table 3 Assessment of quality of studies
Selection Comparability Outcome assessment
Author Year 1 2 3 4 5 6 7 Score
Kon 2007 * * * * ** * - *******
Zhao 2008 - * * ** * * - ******
Reicher 2007 * * * ** ** * - ********
Vassiliades 2009 * * * ** * * * ********
Delhaye 2010 * * * ** * * - *******
Hu 2010 * * * ** ** * * *********
Halkos 2011 * * * * * * - ******
Bachinsky 2012 - * * ** ** * - *******
Leacche 2012 - * * ** * * - ******
-:zero point, *: One point, **: Two points.
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ICU (29.99 vs.47.85 h; WMD: −17.47 h; 95% CI: −31.01 to
−3.93; P = 0.01), LoS in hospital (5.44 vs. 7.30 days; WMD:
−1.77 days; 95% CI, −3.07 to −0.46; P = 0.008), and fewer
instances of RBC transfusion (0.26 vs. 1.55U; WMD: −1.25
U; 95% CI, −1.62 to −0.88; P < 0.001) (Table 5).Table 4 Baseline characteristics of Patients in the Studies incl
Author Group N Age (y) Male (%) Diabetes (%) Hy
Kon HCR 15 61 ± 10 73 27 87
CABG 30 65 ± 10 63 40 80
Zhao HCR 112 63(32–85) 71 39 82
CABG 254 63(32–89) 76 39 83
Reicher HCR 13 62 ± 10 80 29 87
CABG 26 64 ± 10 83 41 75
Vassiliades HCR 91 65 ± 14 67 41 82
CABG 4175 63 ± 12 69 37 83
Delhaye HCR 18 62(55–70) 78 45 67
CABG 18 60(53–68) 78 39 78
Hu HCR 104 62 ± 10 11 25 60
CABG 104 62 ± 8 20 27 63
Haloks HCR 147 64 ± 13 62 60 87
CABG 588 64 ± 13 71 64 85
Bachinsky HCR 25 63 ± 11 80 36 72
CABG 27 67 ± 11 59 48 96
Leacche HCR 80 64 76 40 86
CABG 301 63 77 37 83
Popov HCR 18 60 ± 6 86 16 100
CABG 30 59 ± 4 83 17 100
Data between parentheses represent median and 25th and 75th percentiles. Data wLonger-term outcomes (One year of follow-up)
MACCEs occurred in 2.9% (4/137) of patients after HCR
and 11.8% (18/152) of patients with CABG at one year
of follow-up. The ORs for MACCEs were not signifi-
cantly different at one year of follow-up (OR: 0.32; 95%
CI: 0.05–1.89, P = 0.21; Figure 3E ). As shown inuded
























ith ± symbol represent mean and SD.
Figure 2 Forest plot showing a meta-analysis for HCR versus CABG during hospitalization. A. Death B. MI(Myocardial Infarction) C. Stroke D. MACCEs
(Major Adverse Cardiac or Cerebrovascular Events).
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Table 5 Results of meta-analysis of the secondary outcome
Outcome measures Number of studies Patients
(HCR/CABG)
I2 (%) Analysis model Statistics method OR/WMD 95% CI p value
AF 5 468/1274 0 Fixed M-H 0.93 0.70,1.23 0.60
Renal Failure 5 372/1191 0 Fixed M-H 0.64 0.32,1.27 0.20
Intubation Time 3 132/160 93 Random IV −9.95 −18.58,-1.31 0.02
LOS in ICU 6 322/805 85 Random IV −17.47 −31.01,-3.93 0.01
LOS in hospital 5 304/775 82 Random IV −1.77 −3.07,-0.46 0.008
Red Blood Cells Transfusion 3 53/83 0 Fixed IV −1.25 −1.62,-0.88 P<0.00001
OR odds ratio, WMD Weighted mean difference, M–H Mantel–Haenszel, IV inverse variance, CI confidence interval, AF atrial fibrillation, LOS in ICU lengths of stay
in Intensive Care Unit, LOS in hospital lengths of stay in hospital.
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death, MI, Stroke and TVR at one year of follow-up
were not statistically different.Sensitivity analyses and publication bias
Sensitivity analyses were undertaken on the outcomes
mentioned above by re-analyses using a different effects
model by including studies with ≥80 patients in each
group and including non-RCTs with a score >6 as
assessed by the NOS.
Analyses of non-RCTs studies with a score >6 separ-
ately also did not substantively alter the overall result of
our analyses. Moreover, changing the model did not sub-
stantially change the pooled point estimate.
Inclusion of studies with ≥80 patients in each group
did not substantially change the pooled point estimate
except for LoS in ICU and LoS in hospital. Pooling the
outcomes of these studies revealed no significant differ-
ence in the LoS in ICU (WMD: −10.47 h, 95% CI:
−35.00 to 14.07; P = 0.40) or LoS in hospital (WMD:
−0.42 days; 95% CI: −2.19 to 1.34; P = 0.64) between the
two groups.
In summary, the results of sensitivity analyses sup-
ported the credibility of most of the evidences in this
meta-analysis, but the credibility of the evidences about
LoS in ICU and LoS in hospital should be considered
carefully.
Also, we assessed for publication bias of data by Egger’s
test and visual assessment of funnel plots. For the endpoint
of in-hospital MACCEs, Egger’s test revealed P = 0.694,
showing no evidence of publication bias.Discussion
In this meta-analysis, HCR was non-inferior to CABG in
terms of in-hospital and one-year follow-up outcomes of
death, MI, stroke, TVR, MACCEs, and some surgical
complications (including AF and renal failure) whereas
HCR was associated with a reduced need for RBC trans-
fusion as well as shorter LoS in ICU and LoS in hospital
than CABG.We revealed no significant differences in the preva-
lence of in-hospital and one-year follow-up mortality,
MI, stroke, TVR, MACCEs between the two groups,
findings which were consistent with the early results of
an ongoing RCT [15]. In that RCT, there was no mortal-
ity, MACCEs, or TVR in the hospital. The adequate de-
sign of that study (a prospective, randomized pilot trial
to compare HCR with CABG in patients with MCAD)
provided the preliminary data to strengthen the evi-
dences of our study.
The prevalence of in-hospital one-year follow-up mor-
tality, MI, stroke and MACCEs were similar between the
two groups, however, we hypothesized that HCR may be
superior to CABG in terms of long-term MACCEs. Hu
et al. [18] reported a lower prevalence of MACCEs after
HCR compared with on-pump CABG (1.0% vs 9.6%)
after a mean follow-up of 18 months. Shen et al. [13]
also reported that, after a mean follow-up of 3 years, in
the high Euro-SCORE tertile, the prevalence of MACCEs
in the hybrid group was significantly lower than that in
the CABG group (P = 0.030).
As duration of follow-up extends, HCR may be super-
ior to CABG in terms of long-term MACCEs.Several
reasons support this findings mentioned above. Firstly,
avoiding aortic clamping is one of the unique advantages
of the hybrid procedure. Aortic manipulation (a pre-
dictor of postoperative cerebral infarction) is necessary
during on-pump CABG [27]. Secondly, in the hybrid
procedure, the quality of LIMA–LAD grafting is con-
firmed further by prompt angiography and deficiencies
can be corrected immediately and reliably [28-30]. Fi-
nally, the less invasive nature of the hybrid procedure
plays an important part in patient recovery.
Cardiac surgery and administration of contrast dyes
during PCI tends to increase the risk of renal failure.
Hence, we suggest that the prevalence of renal dysfunc-
tion might be higher in patients treated with HCR
compared with those undergoing CABG alone. In this
meta-analysis, however, no significant difference in the
prevalence of renal failure was found between the two
groups. The more stable hemodynamics and better urine
Figure 3 Forest plot showing a meta-analysis for HCR versus CABG at one-year of follow up. A. Death B. MI(Myocardial Infarction) C. Stroke D. TVR
(Target Vessel Revascularization) E. MACCEs (Major Adverse Cardiac or Cerebrovascular Events).
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prevalence of renal failure in the present study [31,32].
In this analysis, the significantly lower requirement of
RBC transfusion in the HCR group was attributed to the
less invasive nature of minimally invasive direct coronary
artery bypass grafting in the hybrid procedure despite
continuous perioperative use of aspirin and perioperative
administration of clopidogerl [12,14,31].
LoS in ICU and LoS in hospital were significantly
shorter in the HCR group in this analysis, so the hybrid
group had a shorter recovery with a substantial reduction
in utilization of hospital resources [33]. This phenomenon
could be explained in two ways. Firstly, a lower require-
ment of blood transfusion and reduced systemic inflam-
mation have been associated with improved postoperative
morbidity in a series of studies comparing minimally inva-
sive and conventional surgery, and probably play a part in
the outcomes of hybrid surgery. Secondly, better myocar-
dial protection (as reflected by a reduction in regional
release of myoglobin and systemic release of troponin I)
might be another mechanism for quicker recovery after
the hybrid procedure [17].
Heterogeneity among studies was observed for several
continuous variables, including LoS in ICU and LoS in
hospital. This heterogeneity may have resulted from var-
iations in the surgeon’s caseload, the learning-curve ef-
fect, the HCR procedure, perioperative management,
and standards regarding hospital discharge among the
included studies.Limitations
This meta-analysis had several limitations. The main
limitation of our meta-analysis was the retrospective na-
ture of the available data. No RCT has been published
but two protocols have been registered (available at http://
www.clinicaltrials.gov/ct2/show/NCT01699048 and http://
www.clinicaltrials.gov/ct2/show/NCT01035567). Ideally, a
meta-analysis should include RCTs only, but inclusion
of high-quality non-RCTs can improve the statistical
power while maintaining an acceptable level of evidence.
Abrahama et al. [34] reported that a meta-analysis of well-
designed comparative non-RCTs of surgical procedures
was as accurate as a meta-analysis of RCTs. Also, evaluation
of publication bias cannot be done in a robust manner with
such few data points, so the statistical power of Egger’s test
to alert suspicion of publication bias was very limited in
our meta-analysis. Therefore, more RCTs comparing HCR
with CABG in patients with MCAD are necessary.
Secondly, the duration of clinical follow-up was lim-
ited to one year in most studies, whereas a meta-analysis
of long-term outcomes was not possible due to insuffi-
cient data [12,13,17,18,20]. Hence, more long-term re-
sults will be necessary for future studies.Thirdly, the definition of endpoints such as MI,
MACCEs, and renal failure in different studies varied to
some degree, which may have weakened the evidences in
our analysis.
Finally, obvious heterogeneity was observed for several
continuous variables. Therefore, the random-effects model
was used.
Conclusion
This meta-analysis suggested that HCR is feasible, safe
and effective for treatment of MCAD, with similar in-
hospital and one-year follow-up outcomes, significantly
lower requirement for RBC transfusion, and faster re-
covery compared with CABG. It may provide a safe and
effective alternative for treating selected patients with
MCAD. However, to validate the long-term results of
HCR for MCAD, more large-scale, multicenter, pro-
spective RCTs are warranted.
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